Thyroid CancerNCT02747888
Hereditary Risk Factors for Thyroid Cancer
A study testing •Referral to Genetic Counselor, if indicated in people with Thyroid Cancer, run by Dana-Farber Cancer Institute at 1 site in United States.
Trial summary
Thyroid cancers can occur sporadically, but can also be found as tumors that cluster in families with other cancers or genetic syndromes. Researchers are studying thyroid cancer in children and families, with a particular interest in understanding genes and other factors that may put individuals at risk for developing… Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Thyroid Cancer
- What is being tested?
- •Referral to Genetic Counselor, if indicated
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 250 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Mar 2016to 1 Mar 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- Individual pediatric patient with current or previous known or suspected thyroid cancer or nodule(s).
- Individual adult patient with current or previous known or suspected thyroid cancer or nodule(s) if they come from a family with a high suspicion of hereditary cancer (as below).
- Individuals from families with a high suspicion of hereditary thyroid cancer:
- Families with a current or previous diagnosis of a thyroid cancer/nodule occurring in childhood (<18 years old).
- Families with a high suspicion of hereditary thyroid cancer/nodules other than above to include:
- Families with thyroid cancer in multiple individuals
- Families with thyroid cancer and a known genetic syndrome
- Families with thyroid cancer and a suspected genetic syndrome (e.g. multiple childhood cancers in the family, multiple primary cancers, multiple endocrinopathies, etc.)
Who cannot join
- Individuals who are unable to give informed consent.
- Individuals who are unable to complete study materials.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Sarah Hunt, MPH contact
United States1 site, 1 recruiting
- Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts, 02115
Junne Kamihara, MD, PhD, 617.632.3044
Junne Kamihara, MD, PhD
About this study
Thyroid cancers can occur sporadically, but can also be found as tumors that cluster in families with other cancers or genetic syndromes. Researchers are studying thyroid cancer in children and families, with a particular interest in understanding genes and other factors that may put individuals at risk for developing thyroid cancer and thyroid nodules.
- In this study, family and medical history information is collected alongside a blood or saliva sample for genetic studies.
- Individuals with a past or present childhood thyroid cancer/nodule or a thyroid cancer suspected to be inherited in their family are invited to participate.
Read the detailed description
The purpose of this research study is to learn more about risk factors for inherited thyroid cancer.
The investigators would like to use the participant DNA to look for alterations in genes. The investigator will perform DNA sequencing and other genetic studies to identify errors in the genes that may contribute to the formation of thyroid nodules and cancer.
- Conditions
- Thyroid Cancer
- Being tested
- •Referral to Genetic Counselor, if indicated
- Keywords
- Thyroid
- Medical subject headings
- Thyroid Neoplasms, Thyroid Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
•Referral to Genetic Counselor, if indicatedGenetic
| Study group | Role | What they receive |
|---|---|---|
| Lower Suspected Familial Predisposition | No intervention | Lower Suspected Familial Predisposition Screening and Enrollment: Consent, Family HX, Medical HX, Blood/Saliva which will categorize by suspected hereditary predisposition: Based on family and medical history. - Sample stored in Biorepository |
| Higher Suspected Familial Predisposition | Experimental | Higher Suspected Familial Predisposition
Screening and Enrollment:
Consent, Family HX, Medical HX, Blood/Saliva which will categorize by suspected hereditary predisposition: Based on family and medical history.
- Specimen Testing and Analysis
•Referral to Genetic Counselor, if indicated Receives: Genetic: •Referral to Genetic Counselor, if indicated |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of participants who have childhood or suspected familial thyroid nodules/cancer
Measured: 2 years
Number of germline mutations identified associated with thyroid cancer predisposition
Measured: 2 years
Prevalence of suspected familial thyroid cancer among those with childhood thyroid nodules/cancer
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Apr 2016 (estimated)
- Study start1 Mar 2016
- Primary completion1 Mar 2029 (estimated)
- Study completion1 Mar 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Thyroid CancerStudies of the same condition, open and under way.
- More trials run by Dana-Farber Cancer InstituteThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 250 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Dana-Farber Cancer Institute
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Junne Kamihara, MD, Dana-Farber Cancer Institute
- Investigators
- Junne Kamihara, MD, PhD, Principal investigator, Dana-Farber Cancer Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02747888
- Sponsor's protocol ID
- 15-159
- Status last verified
- Jun 2026
- First submitted
- 31 Mar 2016
- Last updated
- 11 Jun 2026
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Hereditary Risk Factors for Thyroid Cancer
- ClinicalTrials.gov ID
- NCT02747888
- Acronym / sponsor ID
- 15-159
- Conditions
- Thyroid Cancer
- Keywords
- Thyroid
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 250 participants (estimated)
- Lead sponsor
- Dana-Farber Cancer InstituteUniversity, hospital or other
- Study start
- 1 Mar 2016 (actual)
- Primary completion
- 1 Mar 2029 (estimated)
- Study completion
- 1 Mar 2029 (estimated)
- First posted
- 22 Apr 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Thyroid cancers can occur sporadically, but can also be found as tumors that cluster in families with other cancers or genetic syndromes. Researchers are studying thyroid cancer in children and families, with a particular interest in understanding genes and other factors that may put individuals at risk for developing thyroid cancer and thyroid nodules.
- In this study, family and medical history information is collected alongside a blood or saliva sample for genetic studies.
- Individuals with a past or present childhood thyroid cancer/nodule or a thyroid cancer suspected to be inherited in their family are invited to participate.
Detailed description
The purpose of this research study is to learn more about risk factors for inherited thyroid cancer.
The investigators would like to use the participant DNA to look for alterations in genes. The investigator will perform DNA sequencing and other genetic studies to identify errors in the genes that may contribute to the formation of thyroid nodules and cancer.
Study design
- Primary purpose
- Screening
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Lower Suspected Familial Predisposition | No intervention | –Lower Suspected Familial Predisposition Screening and Enrollment: Consent, Family HX, Medical HX, Blood/Saliva which will categorize by suspected hereditary predisposition: Based on family and medical history. - Sample stored in Biorepository |
| Higher Suspected Familial Predisposition | Experimental | Genetic: •Referral to Genetic Counselor, if indicatedHigher Suspected Familial Predisposition Screening and Enrollment: Consent, Family HX, Medical HX, Blood/Saliva which will categorize by suspected hereditary predisposition: Based on family and medical history. - Specimen Testing and Analysis •Referral to Genetic Counselor, if indicated |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (8 listed)
- Individual pediatric patient with current or previous known or suspected thyroid cancer or nodule(s).
- Individual adult patient with current or previous known or suspected thyroid cancer or nodule(s) if they come from a family with a high suspicion of hereditary cancer (as below).
- Individuals from families with a high suspicion of hereditary thyroid cancer:
Key exclusion criteria (2 listed)
- Individuals who are unable to give informed consent.
- Individuals who are unable to complete study materials.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| •Referral to Genetic Counselor, if indicated | Genetic | Higher Suspected Familial Predisposition |
Primary outcome
Number of participants who have childhood or suspected familial thyroid nodules/cancer
Time frame: 2 years
Number of germline mutations identified associated with thyroid cancer predisposition
Time frame: 2 years
Prevalence of suspected familial thyroid cancer among those with childhood thyroid nodules/cancer
Time frame: 2 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Thyroid Cancer
Enrolling by invitationObservational study
Head and Neck Cancer Strategies
Head and Neck Cancer (H&N), Thyroid Cancer
Not yet recruitingObservational study
Serum Treg/Th17-Related Cytokines and Systemic Inflammatory Indices in Differentiated Thyroid Cancer
Differentiated Thyroid Cancer (DTC), Papillary Thyroid Carcinoma
Not yet recruitingPhase 1/2
177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
Thyroid Cancer
Recruiting
Radiofrequency Ablation Study in LatinX Patients
Thyroid Nodule
RecruitingPhase 2
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
Neoadjuvant Treatment, Thyroid Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Sarah Hunt, MPH contact
Junne Kamihara, MD, PhD principal investigator
Dana-Farber Cancer Institute
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing •Referral to Genetic Counselor, if indicated in people with Thyroid Cancer, run by Dana-Farber Cancer Institute at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 11 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Junne Kamihara, MD, PhD (617.632.3044, junne_kamihara@dfci.harvard.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of participants who have childhood or suspected familial thyroid nodules/cancer (time frame: 2 years). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jun 2026.